Article Published: 30 July 2019 Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT Jan Styczynski, Gloria Tridello, […]on behalf of the Infectious Diseases Working Party EBMT Bone Marrow Transplantation volume 54, pages2060–2071(2019)Cite this article 196 Accesses 4 Altmetric Metricsdetails Abstract The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) between 1997–2016 was analyzed. In multivariate analysis, the risk of development of chronic GVHD was increased for EBV R+/D+ (HR = 1.26; p = 0.003), R+/D− (HR = 1.21; p = 0.044), and R−/D + (HR = 1.21; p = 0.048) in comparison to R−/D− transplants. No significance was shown for other transplant outcomes; however, in univariate analysis, EBV-seropositive patients receiving grafts from EBV-seropositive donors (EBV R+/D+transplants) had inferior transplant outcomes in comparison to EBV-seronegative recipients of grafts from EBV-seronegative donors (EBV R−/D−): inferior overall survival (59.6% vs 65.9%), inferior relapse-free survival (51.1% vs 57.5%), increased incidence of chronic GVHD (49.5% vs 41.8%), and increased incidence of de novo chronic GVHD (30.5% vs 24.0%). In conclusion, an EBV-negative recipient with lymphoma or chronic malignancy can benefit from selection of an EBV-negative donor in context of chronic GVHD, while there are no preferences in donor EBV serostatus for EBV-seropositive recipient.

Additional Metadata
Persistent URL dx.doi.org/10.1038/s41409-019-0627-9, hdl.handle.net/1765/123349
Journal Bone Marrow Transplantation
Citation
Styczynski, J, Tridello, G., Gil, L, Ljungman, P, Mikulska, M, Ward, KN, … Cesaro, S. (2019). Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. Bone Marrow Transplantation, 54(12), 2060–2071. doi:10.1038/s41409-019-0627-9